Home・Lista de Ações・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Abrir

SetorSaúde

104.91 2.15

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

98.73

Máximo

103.88

Indicadores-chave
By Trading Economics
Rendimento	-8.1M -56M
Vendas	2.9M 60M
EPS	-0.83
Margem de lucro	-92.559
Funcionários	414
EBITDA	-7.6M -50M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+34.02% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.4B 7.3B
Abertura anterior	102.76
Fecho anterior	104.91

Sentimento de Notícias

By Acuity

50%

151 / 340 Ranking em Healthcare

Rhythm Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 de jul. de 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 de jul. de 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 de jul. de 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 de jul. de 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 de jul. de 2026, 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 de jul. de 2026, 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 de jul. de 2026, 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 de jul. de 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Comparação entre Pares

Variação de preço

Rhythm Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

34.02% parte superior

Previsão para 12 meses

Média 137.75 USD 34.02%

Máximo 159 USD

Mínimo 105 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Rhythm Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

Comprar

Manter

Vender

Com base em 13 analistas que deram avaliações de ações para Rhythm Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

151 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.